CHU de Québec Research Center, 2705 Boulevard Laurier, RC-9800, Québec, QC G1V 4G2, Canada.
Department of Pediatrics, Université Laval, Québec, QC G1V 0A6, Canada.
Cancers (Basel). 2016 Jun 28;8(7):62. doi: 10.3390/cancers8070062.
Dickkopf-1 (DKK1) is a secreted Wnt/β-catenin pathway antagonist involved in embryogenesis. It was first described 25 years ago for its function in head induction and limb morphogenesis. Since then, this protein has been widely studied in the context of active Wnt/β-catenin signalling during cellular differentiation and development. Dysregulation of DKK1 has been associated with bone pathologies and has now emerged as a potential biomarker of cancer progression and prognosis for several types of malignancies. Reducing the amount of circulating DKK1 may reveal a simple and efficient strategy to limit or reverse cancer growth. This review will provide an overview of the role of Dickkopf-1 in cancer and explore its potential use as a biomarker and therapeutic target.
Dickkopf-1 (DKK1) 是一种分泌型 Wnt/β-catenin 通路拮抗剂,参与胚胎发生。25 年前,它因其在头部诱导和肢体形态发生中的功能而首次被描述。从那时起,在细胞分化和发育过程中,该蛋白在活跃的 Wnt/β-catenin 信号转导方面得到了广泛研究。DKK1 的失调与骨病理学有关,现在已成为多种恶性肿瘤进展和预后的潜在生物标志物。减少循环 DKK1 的量可能揭示出一种限制或逆转癌症生长的简单而有效的策略。本文综述了 Dickkopf-1 在癌症中的作用,并探讨了其作为生物标志物和治疗靶点的潜在用途。